Design Therapeutics (DSGN) Accumulated Expenses (2020 - 2026)

Design Therapeutics has reported Accumulated Expenses for 7 years, with the latest figure at $8.1 million in Q2 2026.

• Accumulated Expenses for Q2 2026 came in at $8.1 million, up 4.72% year-over-year; the trailing twelve-month figure through Jun 2026 was $8.1 million (up 4.72% YoY), and the FY2025 annual result was $10.7 million, up 71.18% from the prior year.
• Accumulated Expenses advanced to $8.1 million in Q2 2026, from $7.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $10.7 million in Q4 2025 and troughed at $3.6 million in Q1 2022.
• A 5-year average of $7.3 million and a median of $7.7 million in 2023 frame the typical range for Accumulated Expenses.
• The widest annual swing landed in 2022, when Accumulated Expenses soared 192.14%; it then slumped 50.08% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $7.8 million in 2022, then decreased by 0.89% to $7.7 million in 2023, then slipped by 18.3% to $6.3 million in 2024, then soared by 71.18% to $10.7 million in 2025, then declined by 24.61% to $8.1 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $8.1 million in Q2 2026, $7.9 million in Q1 2026, and $10.7 million in Q4 2025.